Heidelberg Pharma AG

M&A Activity • Jun 6, 2008

News Details

Ad-hoc | 6 June 2008 07:34

WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE® (CA9-SCAN)

WILEX AG / Alliance/Forecast

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Munich, 6 June 2008 The Munich-based biopharmaceutical company, WILEX AG
(ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard), has signed
a licensing agreement with IBA (Ion Beam Applications S.A.: Reuters IBAB.BR
and Bloomberg IBAB.BB / Brussels, Belgium) for the worldwide marketing,
distribution and sales of its diagnostic product candidate REDECTANE®
(CA9-SCAN). The agreement gives IBA the exclusive global rights and
licenses required for manufacturing and marketing the product.

According to the agreement, WILEX will manufacture the cold antibody and be
responsible for clinical development. IBA will be responsible for
manufacturing by labeling the antibody and will be responsible for
distribution, sales and marketing of REDECTANE®. WILEX will receive an
upfront payment, milestone payments and certain contributions-in-kind.
After the planned market approval, WILEX will get 20% on ex-factory sales
until a sales volume of EUR 7 million is reached. After that WILEX will get
45% on total ex-factory sales.

WILEX retains worldwide co-promotion rights and may use these to co-promote
REDECTANE® to urologists and oncologists. The companies agreed not to
disclose any further details of the agreement. IBA and WILEX had already
entered into a manufacturing agreement for the ongoing Phase III
registration trial in December 2006.

Due to the conclusion of the agreement WILEX revises its guidance. WILEX
now assumes that if projects progress according to plan and no additional
inflows of capital are generated, current liquidity could suffice until the
second calendar quarter of 2009 rather than the previously announced first
calendar quarter of 2009.

---

Information and Explaination of the Issuer to this News:

This communication contains certain forward-looking statements, relating to
the Company’s business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by
general discussion of strategy, plans or intentions of the Company. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

Given these uncertainties, prospective investors and partners are cautioned
not to place undue reliance on such forward-looking statements. We disclaim
any obligation to update any such forward-looking statements to reflect
future events or developments.

Katja Arnold (CIRO)
Manager Investor Relations
WILEX AG
Grillparzerstrasse 10
81675 Munich
Germany
Tel.: +49 89 41 31 38-126
Fax: +49 89 41 31 38-99
Mobile: +49 160 936 030 22
Email: investors@wilex.com

06.06.2008 Financial News transmitted by DGAP

Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---